G Vignir Helgason
Overview
Explore the profile of G Vignir Helgason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalaf A, de Beauchamp L, Kalkman E, Rattigan K, Himonas E, Jones J, et al.
Sci Transl Med
. 2024 Jun;
16(751):eadi5336.
PMID: 38865484
In chronic myeloid leukemia (CML), the persistence of leukemic stem cells (LSCs) after treatment with tyrosine kinase inhibitors (TKIs), such as imatinib, can lead to disease relapse. It is known...
2.
Zarou M, Rattigan K, Sarnello D, Shokry E, Dawson A, Ianniciello A, et al.
Nat Commun
. 2024 Mar;
15(1):1931.
PMID: 38431691
Supporting cell proliferation through nucleotide biosynthesis is an essential requirement for cancer cells. Hence, inhibition of folate-mediated one carbon (1C) metabolism, which is required for nucleotide synthesis, has been successfully...
3.
Dawson A, Zarou M, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, et al.
Nat Commun
. 2024 Feb;
15(1):1090.
PMID: 38316788
Macrophages are fundamental cells of the innate immune system that support normal haematopoiesis and play roles in both anti-cancer immunity and tumour progression. Here we use a chimeric mouse model...
4.
Rattigan K, Brabcova Z, Sarnello D, Zarou M, Roy K, Kwan R, et al.
Nat Commun
. 2023 Aug;
14(1):4634.
PMID: 37591854
Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia (CML) patients, they fail to eradicate disease-initiating...
5.
Rattigan K, Zarou M, Brabcova Z, Prasad B, Zerbst D, Sarnello D, et al.
EMBO Rep
. 2023 Jul;
24(10):e56279.
PMID: 37489735
To fuel accelerated proliferation, leukaemic cells undergo metabolic deregulation, which can result in specific nutrient dependencies. Here, we perform an amino acid drop-out screen and apply pre-clinical models of chronic...
6.
Yang F, Nourse C, Helgason G, Kirschner K
Hemasphere
. 2023 Jun;
7(6):e895.
PMID: 37304939
Specific cell types and, therefore, organs respond differently during aging. This is also true for the hematopoietic system, where it has been demonstrated that hematopoietic stem cells alter a variety...
7.
Woodley K, Dillingh L, Giotopoulos G, Madrigal P, Rattigan K, Philippe C, et al.
Nat Commun
. 2023 Apr;
14(1):2132.
PMID: 37059720
Resistance to standard and novel therapies remains the main obstacle to cure in acute myeloid leukaemia (AML) and is often driven by metabolic adaptations which are therapeutically actionable. Here we...
8.
Rattigan K, Zarou M, Helgason G
Blood
. 2023 Jan;
141(21):2553-2565.
PMID: 36634302
Our understanding of cancer metabolism spans from its role in cellular energetics and supplying the building blocks necessary for proliferation, to maintaining cellular redox and regulating the cellular epigenome and...
9.
Parry N, Busch C, Assmann V, Cassels J, Hair A, Helgason G, et al.
Cell Death Discov
. 2022 Nov;
8(1):457.
PMID: 36379918
Dysregulation of the BCL-2 family is implicated in protecting chronic myeloid leukemia (CML) cells from intracellular damage and BCR::ABL1-inhibition with tyrosine kinase inhibitors (TKIs) and may be a viable therapeutic...
10.
Ianniciello A, Helgason G
Autophagy
. 2022 Mar;
18(7):1734-1736.
PMID: 35227175
Minimal residual disease (MRD) refers to a low number of cells that persist anti-cancer treatment and is the major cause of relapse in solid cancers and leukemias. In chronic myeloid...